Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 11:55 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2257–2280 of 5,521 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo once daily Clear all

Conditions: Alzheimer Disease
Interventions: NTRX-07, Placebo; Drug
Lead sponsor: NeuroTherapia, Inc.; Industry
Eligibility: 45 Years to 80 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Gates Mills, Ohio

Conditions: Pain
Interventions: placebo, valdecoxib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 488 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 68
States / cities: Birmingham, Alabama • Northport, Alabama • Glendale, Arizona + 46 more

Conditions: Type 2 Diabetes
Interventions: Saxagliptin, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 572 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 11
States / cities: Concord, California • Sacramento, California • Denver, Colorado + 8 more

Conditions: Depression
Interventions: Armodafinil, Placebo; Drug
Lead sponsor: Cephalon; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 492 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 46
States / cities: Birmingham, Alabama • Anaheim, California • Cerritos, California + 41 more

Conditions: Ureteroscopy, Post Operative Pain
Interventions: Corticosteroid, Placebo; Drug · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Venous Thromboembolism
Interventions: Open-label Semuloparin sodium, Placebo (for Semuloparin sodium), Semuloparin sodium; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 469 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Fibromyalgia
Interventions: DS-5565, Placebo; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 22
States / cities: Phoenix, Arizona • Colton, California • Los Angeles, California + 19 more

Conditions: Alzheimer's Disease
Interventions: ST101, Placebo; Drug
Lead sponsor: Sonexa Therapeutics, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 27
States / cities: Tucson, Arizona • Costa Mesa, California • Redlands, California + 24 more

Conditions: Alzheimer's Disease
Interventions: MK-1942, Donepezil, Placebo; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 4
States / cities: Rogers, Arkansas • Hallandale, Florida • Decatur, Georgia + 1 more

Conditions: Rotator Cuff Tendonitis, Bicipital Tendonitis, Subdeltoid Bursitis of the Shoulder, Subacromial Bursitis of the Shoulder, Medial Epicondylitis of the Elbow, Lateral Epicondylitis of the Elbow, DeQuervain's Tenosynovitis of the Wrist
Interventions: diclofenac sodium, Matching Placebo; Drug
Lead sponsor: Cerimon Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 308 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Overactive Bladder
Interventions: SSR240600C, Placebo, Tolterodine; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 22
States / cities: Phoenix, Arizona • Tuscon, Arizona • San Diego, California + 19 more

Conditions: Bacterial Infections
Interventions: TP-271; Drug
Lead sponsor: Tetraphase Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Alzheimer's Disease With Vascular Pathology
Interventions: CY6463, Placebo; Drug
Lead sponsor: Tisento Therapeutics; Industry
Eligibility: 60 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 5
States / cities: Scottsdale, Arizona • Miami, Florida • Honolulu, Hawaii + 2 more

Conditions: Sore-throat, Common Cold
Interventions: Beekeeper's Propolis Throat Spray, Placebo Throat Spray; Dietary Supplement
Lead sponsor: Beekeeper's Naturals Inc; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Anemia
Interventions: Lenalidomide, Placebo; Drug · Other
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 239 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 7
States / cities: Los Angeles, California • Centralia, Illinois • Lebanon, New Hampshire + 4 more

Conditions: Obesity
Interventions: K-757 120 mg BID and K-833 100 mg BID, K-757 120 mg BID and matching placebo to K-833, Matching placebo to K-757 and matching placebo to K-833; Drug
Lead sponsor: TriGemX Bio, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 22
States / cities: San Diego, California • Stockbridge, Georgia • Topeka, Kansas + 19 more

Conditions: Hypercholesterolemia
Interventions: Atorvastatin, Ezetimibe, Alirocumab, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 314 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 41
States / cities: Anaheim, California • Beverly Hills, California • Mission Viejo, California + 38 more

Conditions: Hypoparathyroidism, Endocrine System Diseases, Parathyroid Diseases
Interventions: TransCon PTH, Placebo for TransCon PTH; Combination Product
Lead sponsor: Ascendis Pharma A/S; Industry
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 5
States / cities: Chicago, Illinois • Rochester, Minnesota • Great Neck, New York + 2 more

Conditions: Anxiety Disorders,Generalized Anxiety Disorder
Interventions: Escitalopram, Placebo; Drug · Other
Lead sponsor: AbbVie; Industry
Eligibility: 7 Years to 17 Years
Enrollment: 273 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 39
States / cities: Dothan, Alabama • Little Rock, Arkansas • Rogers, Arkansas + 35 more

Conditions: Attention Deficit Hyperactivity Disorder
Interventions: TC-5619-238 5mg, TC-5619-238 25mg, Placebo; Drug
Lead sponsor: Targacept Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 14
States / cities: Beverly Hills, California • National City, California • Colorado Springs, Colorado + 9 more

Conditions: EPP, XLP
Interventions: Placebo, MT-7117 Low Dose, MT-7117 High Dose; Drug
Lead sponsor: Tanabe Pharma America, Inc.; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 184 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 10
States / cities: Huntington Beach, California • Miami, Florida • Brighton, Massachusetts + 7 more

Conditions: Breast Cancer
Interventions: Letrozole, Placebo; Drug · Other
Lead sponsor: NSABP Foundation Inc; Network
Eligibility: 18 Years to 120 Years · Female only
Enrollment: 3,966 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2025
U.S. locations: 777
States / cities: Anniston, Alabama • Mobile, Alabama • Anchorage, Alaska + 523 more

Conditions: Relapsing Multiple Sclerosis (RMS)
Interventions: Ublituximab, Teriflunomide, Oral Placebo, IV Placebo; Biological · Drug
Lead sponsor: TG Therapeutics, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 549 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 14
States / cities: Carlsbad, California • Long Beach, California • Pasadena, California + 11 more

Conditions: Type 2 Diabetes
Interventions: Pioglitazone, Placebo; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 70 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: San Antonio, Texas

Search by objective public record fields.

A Multiple Dose Study of the Safety and Pharmacokinetics of NTRX-07

Double-Blind, Randomized Study Of The Analgesic Efficacy And Safety Of Valdecoxib 20 Mg Daily And Valdecoxib 20 Mg Twice Daily Compared To Placebo For Management Of Acute Postsurgical Pain In Anterior Cruciate Ligament (ACL) Reconstruction

Treatment Effect of Saxagliptin Compared With Placebo in Patients With Type 2 Diabetes and Renal Impairment

Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder

A Study Of Corticosteroid On Postoperative Pain After Ureteroscopy For Urinary Calculi

Evaluation of AVE5026 as Compared to Placebo for the Extended Prophylaxis of Venous Thromboembolism in Patients Having Undergone Hip Fracture Surgery

Safety Study of DS-5565 for Treatment of Fibromyalgia Pain in Subjects With Chronic Kidney Disease

Preliminary Efficacy and Safety Study of ST101 Plus Aricept in Alzheimer's Disease

MK-1942/Donepezil Interactions in Participants With Alzheimer's Disease (MK-1942-005)

Diclofenac Patch for Treatment of Mild to Moderate Tendonitis or Bursitis

MILADY: A Randomized, Placebo-controlled Safety and Efficacy Trial of SSR240600C in Treatment of Overactive Bladder or Urge Urinary Incontinence.

A Phase 1 TP-271 Oral PK Multiple Ascending Dose Study

A Study of the Effects of CY6463 in Participants With Alzheimer's Disease With Vascular Pathology

A Randomized, Triple-blind, Placebo-controlled Study to Evaluate the Effects of a Throat Spray on the Incidence and Duration of Sickness

A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Lower Risk Myelodysplastic Syndrome (MDS) Without Del 5q

A Study to Evaluate the Safety, Tolerability, and Weight Loss Efficacy of K-757 Alone and in Combination With K-833

Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)

A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH in Adults With Hypoparathyroidism

A Study of Escitalopram in the Treatment of Children and Adolescents With Generalized Anxiety Disorder

Safety & Efficacy of TC-5619 in Adults With Inattentive-predominant Attention Deficit/Hyperactivity Disorder (ADHD)

Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria or X-Linked Protoporphyria

Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer

Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) ( ULTIMATE 1 )

Effect of Pioglitazone on TIMP-3 and TACE in Type 2 Diabetes